T. Rowe Price Associates’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $106K | Buy |
+26,299
| New | +$106K | ﹤0.01% | 2879 |
|
|
2020
Q1 | – | Sell |
-647,174
| Closed | -$3.52M | – | 2521 |
|
|
2019
Q4 | $3.52M | Sell |
647,174
-949,395
| -59% | -$5.17M | ﹤0.01% | 1463 |
|
|
2019
Q3 | $4.81M | Sell |
1,596,569
-165,679
| -9% | -$499K | ﹤0.01% | 1381 |
|
|
2019
Q2 | $6.59M | Sell |
1,762,248
-203,794
| -10% | -$762K | ﹤0.01% | 1364 |
|
|
2019
Q1 | $7.9M | Sell |
1,966,042
-20,121
| -1% | -$80.9K | ﹤0.01% | 1349 |
|
|
2018
Q4 | $7.29M | Sell |
1,986,163
-2,010
| -0.1% | -$7.38K | ﹤0.01% | 1354 |
|
|
2018
Q3 | $17.1M | Sell |
1,988,173
-11,926
| -0.6% | -$102K | ﹤0.01% | 1275 |
|
|
2018
Q2 | $22M | Sell |
2,000,099
-4,576
| -0.2% | -$50.2K | ﹤0.01% | 1172 |
|
|
2018
Q1 | $23.1M | Buy |
2,004,675
+1,698,459
| +555% | +$19.6M | ﹤0.01% | 1136 |
|
|
2017
Q4 | $3.17M | Buy |
306,216
+300
| +0.1% | +$3.11K | ﹤0.01% | 1473 |
|
|
2017
Q3 | $4.88M | Sell |
305,916
-38,685
| -11% | -$617K | ﹤0.01% | 1426 |
|
|
2017
Q2 | $4.17M | Sell |
344,601
-450,795
| -57% | -$5.46M | ﹤0.01% | 1433 |
|
|
2017
Q1 | $16.5M | Buy |
795,396
+182,819
| +30% | +$3.8M | ﹤0.01% | 1229 |
|
|
2016
Q4 | $8.76M | Sell |
612,577
-25,720
| -4% | -$368K | ﹤0.01% | 1339 |
|
|
2016
Q3 | $10.5M | Buy |
638,297
+3,409
| +0.5% | +$56.1K | ﹤0.01% | 1304 |
|
|
2016
Q2 | $8.8M | Sell |
634,888
-100
| -0% | -$1.39K | ﹤0.01% | 1312 |
|
|
2016
Q1 | $8.95M | Buy |
+634,988
| New | +$8.95M | ﹤0.01% | 1293 |
|